Epidemiology of myositis.

IF 5.2 2区医学 Q1 RHEUMATOLOGY

Current opinion in rheumatology Pub Date : 2025-03-01 Epub Date: 2024-12-10 DOI:10.1097/BOR.0000000000001076

Fnu Duremala, Eleni Tiniakou, James Andrews

{"title":"Epidemiology of myositis.","authors":"Fnu Duremala, Eleni Tiniakou, James Andrews","doi":"10.1097/BOR.0000000000001076","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review aims to synthesize recent developments in the epidemiology of idiopathic inflammatory myopathies (IIMs), focusing on incidence, prevalence, disease classification, and clinical outcomes.Recent findings: IIM is a rare group of autoimmune diseases characterized by muscle weakness and systemic involvement, with incidence rates ranging from 0.2 to 2 cases per 100 000 person-years. The role of myositis-specific autoantibodies (MSAs) in stratifying disease risk and prognosis is increasingly recognized, such as in anti-MDA5 positive DM, which is associated with a high risk of rapidly progressive interstitial lung disease. Furthermore, patients with IIM exhibit elevated risks of comorbidities, including cardiovascular disease and malignancy.Summary: IIM diseases are complex disorders with significant health impacts, necessitating enhanced awareness and research. Improved classification and understanding of MSAs are crucial for earlier diagnosis and tailored therapeutic strategies. Continued epidemiological research is essential to elucidate underlying mechanisms and inform future interventions, ultimately aiming to enhance the quality of life and clinical outcomes for affected patients.","PeriodicalId":11145,"journal":{"name":"Current opinion in rheumatology","volume":" ","pages":"121-127"},"PeriodicalIF":5.2000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/BOR.0000000000001076","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/10 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This review aims to synthesize recent developments in the epidemiology of idiopathic inflammatory myopathies (IIMs), focusing on incidence, prevalence, disease classification, and clinical outcomes.

Recent findings: IIM is a rare group of autoimmune diseases characterized by muscle weakness and systemic involvement, with incidence rates ranging from 0.2 to 2 cases per 100 000 person-years. The role of myositis-specific autoantibodies (MSAs) in stratifying disease risk and prognosis is increasingly recognized, such as in anti-MDA5 positive DM, which is associated with a high risk of rapidly progressive interstitial lung disease. Furthermore, patients with IIM exhibit elevated risks of comorbidities, including cardiovascular disease and malignancy.

Summary: IIM diseases are complex disorders with significant health impacts, necessitating enhanced awareness and research. Improved classification and understanding of MSAs are crucial for earlier diagnosis and tailored therapeutic strategies. Continued epidemiological research is essential to elucidate underlying mechanisms and inform future interventions, ultimately aiming to enhance the quality of life and clinical outcomes for affected patients.

查看原文本刊更多论文

肌炎的流行病学。

综述目的：本综述旨在综合特发性炎症性肌病（IIMs）流行病学的最新进展，重点介绍发病率、患病率、疾病分类和临床结局。最近发现：IIM是一组罕见的自身免疫性疾病，其特征是肌肉无力和全身受累，发病率为每10万人年0.2至2例。肌炎特异性自身抗体（msa）在分层疾病风险和预后中的作用越来越被认识到，例如抗mda5阳性DM与快速进展的间质性肺疾病的高风险相关。此外，IIM患者出现合并症的风险增加，包括心血管疾病和恶性肿瘤。摘要：IIM疾病是具有重大健康影响的复杂疾病，需要加强认识和研究。提高对msa的分类和理解对于早期诊断和制定治疗策略至关重要。持续的流行病学研究对于阐明潜在的机制和为未来的干预提供信息至关重要，最终旨在提高受影响患者的生活质量和临床结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current opinion in rheumatology 医学-风湿病学

CiteScore

9.70

自引率

2.00%

发文量

审稿时长

6-12 weeks

期刊介绍： A high impact review journal which boasts an international readership, Current Opinion in Rheumatology offers a broad-based perspective on the most recent and exciting developments within the field of rheumatology. Published bimonthly, each issue features insightful editorials and high quality invited reviews covering two or three key disciplines which include vasculitis syndromes, medical physiology and rheumatic diseases, crystal deposition diseases and rheumatoid arthritis. Each discipline introduces world renowned guest editors to ensure the journal is at the forefront of knowledge development and delivers balanced, expert assessments of advances from the previous year.